About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
MYL - Mylan N.V.| Previous Close | $14.26 | Open | $14.11 |
| Volume | 3.18M | Market Cap | 8.871B |
| Yield | Last Dividend |
| Biocon says probe on Malaysia manufactur... | 03/31/20 |
| BENGALURU: Biocon???s insulin manufacturing facility in Malaysia has received an establishment inspection report (EIR) from the USFDA indicating that ... | |
| Mylan, Lupin Get Positive CHMP Opinion f... | 03/27/20 |
| By Colin Kellaher Mylan N.V. and Lupin Ltd. Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended app... | |
| Top Analyst Upgrades and Downgrades: Ame... | 03/27/20 |
| No summary available. | |
| Drugmakers Mylan, Pfizer delay merger du... | 03/26/20 |
| Drugmaker Mylan NV's merger with Pfizer Inc's off-patent branded drug unit, Upjohn, would now close in the second half of 2020 due to the delays surro... | |
| Mylan and Pfizer Provide Update Regardin... | 03/26/20 |
| HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the ... | |
| Mylan Announces Additional Efforts to Su... | 03/25/20 |
| HERTFORDSHIRE, England and PITTSBURGH, March 25, 2020 /PRNewswire/ -- Mylan (NASDAQ: MYL) today announced that, in its ongoing effort to support patie... | |
| Mylan, Teva in Focus As Chloroquine Bein... | 03/20/20 |
| Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to con... | |
| A Mumbai co is working on potential Covi... | 03/20/20 |
| MUMBAI: Lasa SuperGenerics, a manufacturer of active pharmaceutical ingredients (APIs), said it will team up with the Institute of Chemical Technology... | |
| Elon Musk and President Trump are toutin... | 03/19/20 |
| Demand for malaria pills has skyrocketed, based on the hopes that the drug may be able to treat COVID-19 , the disease caused by the coronavirus pande... | |
| Hopes high for Mylan???s Upjohn merger e... | 03/18/20 |
| Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer (PFE). The ... | |
| Pharma department tells companies to ste... | 03/12/20 |
| At a meeting held with the manufacturers on Wednesday, a committee of experts constituted by the Department of Pharmaceuticals (DoP) asked companies s... | |
| Biocon, Mylan win US court ruling that n... | 03/11/20 |
| Bengaluru: Biocon, with its partner Mylan, has won a US court ruling that invalidated rival Sanofi???s patent on the insulin Glargine device, removing... | |
| Mylan-Upjohn Merger in Focus, Coronaviru... | 03/09/20 |
| Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's suppl... | |
| USFDA accepts proposed biosimilar applic... | 03/09/20 |
| Read more about USFDA accepts proposed biosimilar application by Mylan, Biocon for review on Business Standard. The application seeks approval of Beva... | |
| US FDA accepts Biocon's cancer drug appl... | 03/08/20 |
| BENGALURU: The US Food and Drug Administration (FDA) has accepted Mylan???s Biologics License Application (BLA) for proposed biosimilar to Avastin, be... | |
| The Daily Biotech Pulse: Breakthrough De... | 03/06/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5... | |
| The Daily Biotech Pulse: Trevana Pain Dr... | 03/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) ... | |
| The Daily Biotech Pulse: Takeda Jumps In... | 03/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) ... | |
| Stocks to Watch: Twitter, Harley-Davidso... | 03/02/20 |
| Twitter, Harley-Davidson, American Express and Mylan are some of the companies with shares expected to trade actively in Monday???s session. | |
| Mylan (MYL) Tops Q4 Earnings Estimates | 02/27/20 |
| Mylan (MYL) delivered earnings and revenue surprises of 8.53% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues... | |
| Mylan posts 60per cent fall in fourth-qu... | 02/27/20 |
| Drugmaker Mylan NV reported a nearly 60per cent fall in its fourth-quarter profit on Thursday, hurt by a higher income tax provision. | |
| Mylan posts 60% fall in fourth-quarter p... | 02/27/20 |
| https://www.investing.com/news/stock-market-news/mylan-posts-60-fall-in-fourthquarter-profit-2096367 | |
| Mylan Reports Fourth Quarter and Full Ye... | 02/27/20 |
| HERTFORDSHIRE, England and PITTSBURGH, Feb. 27, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the fourth qua... | |
| Mylan and Pfizer Announce Appointment of... | 02/27/20 |
| HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, ... | |
| The Zacks Analyst Blog Highlights: Johns... | 02/24/20 |
| The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries | |
| Mylan to Release 2019 Fourth Quarter, Fu... | 02/18/20 |
| HERTFORDSHIRE, England and PITTSBURGH, Feb. 18, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it wi... | |
| Sanofi urges SCOTUS to stay Lantus paten... | 02/10/20 |
| Pharmaceutical company Sanofi has asked the U.S. Supreme Court to halt its patent litigation with Mylan NV over the diabetes drug Lantus while the jus... | |
| Biogen Soars on Patent Win for MS Drug T... | 02/06/20 |
| The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling... | |
| NPPA seeks clarification on Gilead's dru... | 01/30/20 |
| NEW DELHI: India???s drug pricing regulator has raised a red flag against price exemption plea made by US drug maker Gilead Sciences for its medicine ... | |
| Should Value Investors Consider Mylan N.... | 01/20/20 |
| Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more. | |
| Hold rating | 12:00 AM |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $23.00 to $18.00 | |
| Strong Buy rating | 03/27/20 |
| RBC Capital maintains Outperform rating and lowers Price Target from $27.00 to $26.00 | |
| Buy rating | 01/27/20 |
| SVB Leerink downgrades from Outperform to Market Perform rating and announces Price Target of $24.00 | |
| Strong Buy rating | 01/07/20 |
| RBC Capital maintains Outperform rating and raises Price Target from $25.00 to $27.00 | |
| Hold rating | 11/07/19 |
| JP Morgan downgrades from Overweight to Equal-Weight rating and lowers Price Target from $25.00 to $18.00 | |
| Hold rating | 11/07/19 |
| Morgan Stanley downgrades from Overweight to Equal-Weight rating and lowers Price Target from $25.00 to $18.00 | |
| Date | 2020-02-27 (AMC) | Est. (EPS/Rev.) | $1.28/ 3.23B |
| Actual (EPS/Rev.) | $1.40/ $3.19 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| The profit machine | Gino Baldassano | 70.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Options Edge | Calvin Moore | 62.00 % | Subscribe |
| TopFlight Trades - Premium (Options) | Eric Cunningham | 51.00 % | Follow |
| Options Mann | Thomas Mann | 40.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
